Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report

DNA mismatch repair deficient (dMMR) and microsatellite instable (MSI) metastatic colorectal cancer (mCRC) can be successfully treated with FDA- and EMA-approved immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab (as single agents targeting the anti-programmed cell death protein-1 (PD-1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Krekeler, Carolin, Wethmar, Klaus, Mikesch, Jan-Henrik, Kerkhoff, Andrea, Menck, Kerstin, Lenz, Georg, Schildhaus, Hans-Ulrich, Wessolly, Michael, Hoffmann, Matthias W., Pascher, Andreas, Asmus, Inga, Wardelmann, Eva, Bleckmann, Annalen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418401/
https://www.ncbi.nlm.nih.gov/pubmed/37569431
http://dx.doi.org/10.3390/ijms241512056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418401/
https://www.ncbi.nlm.nih.gov/pubmed/37569431
http://dx.doi.org/10.3390/ijms241512056

Ejemplares similares